Cancer Therapy

Pro-Pharmaceuticals updates Davanat clinical trials progress

Published in Clinical Trials Week, September 25th, 2006

Pro-Pharmaceuticals, Inc. (PRW) has updated its clinical trials progress, reporting that Phase I and Phase II clinical trials of Davanat with 5-FU data shows 1 patient with an objective partial tumor response and 20 patients stabilized out of 60. These patients had tumors on average of 100mm, had a minimum of 12 weeks to live and were refractory to chemotherapy, including 5-FU.

One patient from Phase II continued to be treated for 26 weeks. A cholangiocarcinoma patient from the Phase I trial was treated for more than 56 weeks. The results of these studies compare very well and exceed results from similar recent studies in the same patient populations.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2006-09-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry